Skye Bioscience Inc (SKYE)

[cjarmstrong]

My research wasn't as thorough as it should have been, I only looked into bioavailability and was surprised/concerned that the research was that old. Concerned that the formulation wasn't successfully commercialized and then realizing the patent filed in 1993 had expired.

However, after reading your post today I found a chart that you no doubt have already seen comparing plasma concentrations among three subjects who were administered THC-HS suppositories. It's on page 132 of the book "Marihuana and Medicine"

https://books.google.ca/books?id=AYH5BwAAQBAJ&printsec=frontcover#v=onepage&q&f=false

Higher peak/shorter duration of action than NB1222. Just like NB1111 (same prodrug as NB1222, THC-VHS) their prodrugs have a lower effect but longer duration of action. So I'm not concerned with the expired patent, but still a bit skeptical if NB1222 will be commercialized. The formulation Elsohly patented in 1993 was good, but there's a lot more attention on the cannabinoid space now.